Tags

Type your tag names separated by a space and hit enter

Fingolimod for the treatment of relapsing multiple sclerosis.
Expert Rev Neurother. 2011 Feb; 11(2):165-83.ER

Abstract

Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is a sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes, resulting in a downregulation of the receptor and a reversible sequestration of lymphocytes in lymphoid tissue. Effector memory T cells are not sequestered so that immune surveillance may be minimally affected. Two large-scale Phase III clinical trials have demonstrated the efficacy of fingolimod compared with placebo and intramuscular interferon β-1a in relapsing-remitting multiple sclerosis. Due to its mechanism of action, fingolimod administration may be associated with first-dose bradycardia and macular edema. Therefore, patients should be observed for 6 h at the time of their first dose and undergo ophthalmologic evaluation prior to treatment initiation and at 3-4 months after initiation.

Authors+Show Affiliations

The Multiple Sclerosis and Movement Disorders Center at Advance Neurology at Cornerstone Health Care, Winston-Salem, NC 27006, USA. douglas.jeffery@cornerstonehealthcare.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21158700

Citation

Jeffery, Douglas R., et al. "Fingolimod for the Treatment of Relapsing Multiple Sclerosis." Expert Review of Neurotherapeutics, vol. 11, no. 2, 2011, pp. 165-83.
Jeffery DR, Markowitz CE, Reder AT, et al. Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother. 2011;11(2):165-83.
Jeffery, D. R., Markowitz, C. E., Reder, A. T., Weinstock-Guttman, B., & Tobias, K. (2011). Fingolimod for the treatment of relapsing multiple sclerosis. Expert Review of Neurotherapeutics, 11(2), 165-83. https://doi.org/10.1586/ern.10.193
Jeffery DR, et al. Fingolimod for the Treatment of Relapsing Multiple Sclerosis. Expert Rev Neurother. 2011;11(2):165-83. PubMed PMID: 21158700.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fingolimod for the treatment of relapsing multiple sclerosis. AU - Jeffery,Douglas R, AU - Markowitz,Clyde E, AU - Reder,Anthony T, AU - Weinstock-Guttman,Bianca, AU - Tobias,Kathy, Y1 - 2010/12/16/ PY - 2010/12/17/entrez PY - 2010/12/17/pubmed PY - 2011/8/30/medline SP - 165 EP - 83 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 11 IS - 2 N2 - Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is a sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes, resulting in a downregulation of the receptor and a reversible sequestration of lymphocytes in lymphoid tissue. Effector memory T cells are not sequestered so that immune surveillance may be minimally affected. Two large-scale Phase III clinical trials have demonstrated the efficacy of fingolimod compared with placebo and intramuscular interferon β-1a in relapsing-remitting multiple sclerosis. Due to its mechanism of action, fingolimod administration may be associated with first-dose bradycardia and macular edema. Therefore, patients should be observed for 6 h at the time of their first dose and undergo ophthalmologic evaluation prior to treatment initiation and at 3-4 months after initiation. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/21158700/Fingolimod_for_the_treatment_of_relapsing_multiple_sclerosis_ L2 - http://www.tandfonline.com/doi/full/10.1586/ern.10.193 DB - PRIME DP - Unbound Medicine ER -